Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents? – ILCN.org (ILCN/WCLC)
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
Related Articles
Excuse me, What? Top Recommendations for Effective Patient Communication in Oncology: Live from TexasLung25 | IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Eric Singhi…
Foritinib Gains Momentum in China for ALK-positive NSCLC – ILCN.org (ILCN/WCLC)
China’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial.
From Grief to Global Change: How the STARS Program Empowers Advocates to Drive Lung Cancer Research – ILCN.org (ILCN/WCLC)
Discover how to turn your personal experience with lung cancer into meaningful change with the IASLC STARS program.
Smoking Cessation in Lung Cancer Screening: The Latest Randomized Controlled Trial Evidence – ILCN.org (ILCN/WCLC)
The SCALE trials aim to uncover key elements of successful smoking cessation programs by evaluating various intervention combinations.
ELCC 2025: Insights and Review of the Data | IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and Dr. Corey Langer discuss data presented at the recent European Lung Cancer Congress…
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award – ILCN.org (ILCN/WCLC)
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide…
Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy – ILCN.org (ILCN/WCLC)
Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress.
LCC in Italian: Virtual Tumor Board – Resectable Stage III NSCLC | IASLC
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a discussion in Italian with Dr. Cecilia Pompili and Dr.…
Smoking Cessation at Lung Examination: Lessons Learned and Next Steps from the NCI SCALE Collaboration – Part 2 | IASLC
The U.S. Preventive Services Task Force recommends lung cancer screening (LCS) with low-dose computed tomography for adults aged 50 to 80 years who have smoked…
Potential targeted therapy for pediatric brain cancer identified by Dana-Farber/Boston Children’s team | Dana-Farber Cancer Institute
An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in…
